Opinion|Videos|March 4, 2025
New Nonsteroidal Topical Treatment Options for Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD, Randy Alevi, DO
Panelists discuss recent topical atopic dermatitis therapies, which include roflumilast (PDE4 inhibitor, age ≥ 6 years), ruxolitinib (JAK inhibitor, age ≥ 12 years), and tapinarof (hydrocarbon receptor agonist, age ≥ 2 years). Treatment selection considers disease severity, age, affected areas, comorbidities, and previous therapy responses.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- There have been several new topical therapies approved in recent years. Discuss these treatments, how they work to treat atopic dermatitis, as well as an overview of efficacy and safety data.
- Topical roflumilast (0.15% cream): FDA approved for patients 6 years or older
- PDE4 inhibitor; INTEGUMENT-1 and INTEGUMENT-2
- Topical ruxolitinib (1.5% cream): FDA approved for patients 12 years or older
- JAK inhibitor; TRuE-AD1 and TRuE-AD2
- Topical tapinarof (1% cream): FDA approved for patients 2 years or older
- Hydrocarbon receptor agonist; ADORING 1 and ADORING 2
- Topical roflumilast (0.15% cream): FDA approved for patients 6 years or older
- What patient factors do you consider when selecting a treatment option?
- How do you decide among all the available topical treatment options for your patients?
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
3
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
4
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
5